Project Grant R01HL180388
- Federal Grant Award Summary Yale University received a $147,486 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded on July 15, 2025, with a completion date of June 30, 2028. The grant supports research to define the role of G3BP1, an RNA binding protein (RBP), in vascular development and blood vessel formation. The research will utilize a novel G3BP1 loss-of-function mutant zebrafish model to...
- Federal Project Grant Award Summary Yale University received a $958,850 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded September 1, 2025, with a completion date of May 31, 2029. This research project focuses on investigating interleukin-1 (IL-1) signaling mechanisms in critically ill children with bronchiolitis to identify disease severity markers and develop therapeutic interventions. The...
- Federal Project Grant Award Summary Yale University received a $671,373 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective July 1, 2026, through March 31, 2030. The award funds research investigating ferroptosis regulation in lung inflammation and injury, with the primary deliverable being scientific findings on the mechanisms by which pulmonary inflammation damages alveolar cells. The project...
- Federal Grant Award Summary Yale University received a $706,573 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective August 1, 2025, through May 31, 2029. The award supports the development of novel statistical methodologies for analyzing multiple and composite outcomes in cluster-randomized trials (CRTs) using win estimands (net benefit, win ratio, win odds). The project will create a suite of...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded Yale University a Project Grant of $126,177 under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the role of primary cilia protein Intraflagellar Transport 88 (IFT88) in smooth muscle cell phenotype and vascular remodeling. The grant, awarded June 17, 2026, with completion scheduled for April 30, 2028, supports research aimed at addressing a significant gap in understanding how...
- Federal Project Grant Award Summary Yale University received a $806,978 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective August 1, 2025, with a completion date of June 30, 2030. The award funds research investigating Plasminogen Activator Inhibitor 1 (PAI-1) as a therapeutic target for maternal endothelial dysfunction in preeclampsia. The research aims to develop novel therapeutic strategies...
- Federal Project Grant Award Summary Harvard College, through its Office for Sponsored Programs Division, received a $151,040 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The award, effective February 5, 2026, with completion targeted for November 30, 2028, funds research investigating the role of Tolloid (TLD) proteases in atrial fibrosis pathogenesis. The project delivers basic science research...
- Federal Grant Award Summary Yale University received a $1.498 million Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded September 23, 2025, with a completion date of August 31, 2027. The award funds research investigating the molecular mechanisms of sex differences in scleroderma-associated interstitial lung disease (SSc-ILD), specifically examining the role of mitochondrial DNA (mtDNA) and Toll-like...
- Federal Project Grant Award Summary Yale University received a $347,112 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective September 5, 2025, with completion targeted for August 31, 2030. The award funds the PAP-FLOW Study, a clinical research initiative investigating the impact of positive airway pressure (PAP) therapy on myocardial blood flow in adults with obstructive sleep apnea (OSA) who are at...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded The Leland Stanford Junior University a $2.44 million Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) on August 15, 2025, with a completion date of July 31, 2030. This five-year award supports research to identify causal gene programs that influence vascular diseases, specifically coronary artery disease and pulmonary arterial hypertension. The project will deliver advanced...
Yale University received a $1.68M Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded July 1, 2026, with completion targeted for April 30, 2028. The award funds basic science research investigating the developmental cellular and molecular mechanisms underlying Circle of Willis (CW) formation and maintenance—a critical collateral circulatory system in the brain that provides redundant oxygenated blood supply and protects against cerebrovascular disease. The research leverages zebrafish models and human induced pluripotent stem cell (iPSC)-derived vascular organoids to elucidate how microRNA-125A (mir-125a) regulates embryonic brain angiogenesis and how mitochondrial metabolism influences CW artery formation and stability. The project addresses fundamental gaps in understanding developmental origins of anatomical variations in the Circle of Willis, which are surprisingly common in human populations yet remain largely unexplained at the molecular level. By identifying how mir-125a loss-of-function leads to incomplete CW formation through altered mitochondrial biogenesis and oxidative metabolism, the research aims to establish whether these vascular variations are established during embryonic development and whether they could be corrected to protect against vascular stress. Deliverables include mechanistic discoveries regarding the genotype-phenotype relationship in CW development, experimental validation across multiple model systems, and foundational knowledge to support future therapeutic interventions for cerebrovascular disease prevention.Federal Project Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $1.7m | 6/10/26 |